Search Results | Blood | American Society of Hematology

1-20 of 73

2 3 4

Sort by

Sort Order Select

Journal Articles

Effect of Mutation Allele Frequency on the Risk Stratification of Myelodysplastic Syndrome Patients

Wan Hsuan Lee, Chien-Chin Lin, Cheng-Hong Tsai, Mei-Hsuan Tseng, Yuan-Yeh Kuo, Ming-Chih Liu, Jih-Luh Tang, Hsun-I Sun, Yi-Kuang Chuang, Wen-Chien Chou, Hsin-An Hou, Hwei-Fang Tien

Blood (2022) 140 (Supplement 1): 6932–6933.

DOI: https://doi.org/10.1182/blood-2022-159872

Published: 2022

Journal Articles

Conditional Knock-out of Phf6 Decreases CD44 Expression on Naïve CD4 + T Cells and Skews the Differentiation Toward Regulatory T Cells in Mice

Tsung-Chih Chen, Chia-Lang Hsu, Chi-Yuan Yao, Yu-Ren Chen, Yueh-Chwen Hsu, Chein-Jun Kao, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien

Blood (2022) 140 (Supplement 1): 2635–2636.

DOI: https://doi.org/10.1182/blood-2022-155984

Published: 2022

Journal Articles

A Three Gene Leukemic Stem Cell Signature Score Is Robustly Prognostic in Chronic Myelomonocytic Leukemia

Yu-Hung Wang, Chi-Yuan Yao, Chien-Chin Lin, Kristian Gurashi, Fabio Amaral, Andres Jerez, Tim C.P Somervaille, Hsin-An Hou, Wen-Chien Chou, Kiran Batta, Hwei-Fang Tien, Daniel H Wiseman

Blood (2022) 140 (Supplement 1): 1104–1105.

DOI: https://doi.org/10.1182/blood-2022-165449

Published: 2022

Journal Articles

Prognostic Relevance of Adult Acute Myeloid Leukemia Patients According to the 2022 European Leukemianet Risk Stratiﬁcation

Min Yen Lo, Cheng-Hong Tsai, Yuan-Yeh Kuo, Mei-Hsuan Tseng, Yen-Ling Peng, Cheng-An Hsu, Hsun-I Sun, Yi-Kuang Chuang, Wen-Chien Chou, Hsin-An Hou, Hwei-Fang Tien

Blood (2022) 140 (Supplement 1): 130–131.

DOI: https://doi.org/10.1182/blood-2022-168522

Published: 2022

Journal Articles

Cost-Effectiveness Analysis of Frontline Treatment with Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Yu-Hua Fu, Shang-Ju Wu, Elise Chia-Hui Tan, Chi-Chuan Wang, Kibum Kim, Wen-Chien Chou, Fang-Ju Lin

Blood (2022) 140 (Supplement 1): 10808–10809.

DOI: https://doi.org/10.1182/blood-2022-162980

Published: 2022

Journal Articles

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Blood (2022) 140 (17): 1845–1857.

DOI: https://doi.org/10.1182/blood.2021014586

Published: 2022

Includes: Supplemental data

Journal Articles

Metabolic Profiling Reveals Cellular Reprogramming of Acute Myeloid Leukemia By Omipalisib through Serine Synthesis Pathway

Liang-In Lin, Tseng Chiyang, Yu-Hsuan Fu, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien

Blood (2021) 138 (Supplement 1): 3296.

DOI: https://doi.org/10.1182/blood-2021-149200

Published: 2021

Journal Articles

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Blood (2021) 138 (Supplement 1): 700.

DOI: https://doi.org/10.1182/blood-2021-145379

Published: 2021

Journal Articles

RUNX1 Expression Can be Complementary to RUNX1 Mutation in MDS Prognostication

Yu-Hung Wang, Chi-Yuan Yao, Chien-Chin Lin, Chia-Lang Hsu, Hsin-An Hou, Hwei-Fang Tien, Wen-Chien Chou

Blood (2021) 138 (Supplement 1): 2614.

DOI: https://doi.org/10.1182/blood-2021-145422

Published: 2021

Journal Articles

Epidemiology of Light-Chain Amyloidosis: A Population-Based Cohort Study in Taiwan

Hsin-An Hou, Chao-Hsiun Tang, Choo Hua Goh, Sarah Siggins, Shih-Pei Shen, Hong Qiu, Wen-Chien Chou, Yanfang Liu

Blood (2021) 138 (Supplement 1): 1637.

DOI: https://doi.org/10.1182/blood-2021-147660

Published: 2021

Journal Articles

Accurate Prediction of Gene Mutations with Flow Cytometry Immune-Phenotyping By Machine Learning Algorithm

Bor-Sheng Ko, MD PhD, Yu-Fen Wang, MS, Jeng-Lin Li, BS, Hsin-An Hou, Wen-Chien Chou, MD PhD, Hwei-Fang Tien, MD, PhD, Ting-Yu Chang, M.S., Chi-Chun Lee, PhD

Blood (2020) 136 (Supplement 1): 7–8.

DOI: https://doi.org/10.1182/blood-2020-139623

Published: 2020

Journal Articles

Risk Factors for Thrombotic Events in Patients with PNH: A Nested Case-Control Study in the International PNH Registry

Britta Hoechsmann, Regis Peffault De Latour, MD PhD, Anita Hill, Alexander Röth, MD, Timothy Devos, MD, Christopher Patriquin, Wen-Chien Chou, MD PhD, Deepak Jain, Ke Zu, Jong Wook Lee, MD, PhD

Blood (2020) 136 (Supplement 1): 6–8.

DOI: https://doi.org/10.1182/blood-2020-136767

Published: 2020

Journal Articles

Prognostic Prediction with Static-Dynamic Clinical and Pathological Parameters By Machine Learning Algorithm in Acute Lymphoblastic Leukemia

Bor-Sheng Ko, MD PhD, Yu-Fen Wang, MS, Jeng-Lin Li, BS, Hsin-An Hou, Wen-Chien Chou, MD PhD, Hwei-Fang Tien, MD, PhD, Ting-Yu Chang, M.S., Chi-Chun Lee, PhD

Blood (2020) 136 (Supplement 1): 1.

DOI: https://doi.org/10.1182/blood-2020-139766

Published: 2020

Journal Articles

Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

Cheng-Hong Tsai, MD MSc, Feng Ming Tien, MD MSc, Hsin-An Hou, MD PhD, Jia-Hau Liu, MD, Shang-Ju Wu, MD PhD, Yu-Wen Wang, MSc., Chien-Chin Lin, MD, Bor-Sheng Ko, MD PhD, Wen-Chien Chou, MD PhD, Yun-Chu Lin, MD, Chieh-Lung Cheng, MD, Li-Chun Lu, MD PhD, Sung-Hsin Kuo, MD PhD, Ruey-Long Hong, MD PhD, Tai-Chung Huang, MD PhD, Ming Yao, MD

Blood (2020) 136 (Supplement 1): 12.

DOI: https://doi.org/10.1182/blood-2020-138481

Published: 2020

Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci

Blood (2019) 134 (Supplement_1): 14.

DOI: https://doi.org/10.1182/blood-2019-122620

Published: 2019

Journal Articles

Automatic Bone Marrow Cell Identification and Classification By Deep Neural Network

Ta-Chuan Yu, MD, Wen-Chien Chou, MD, PhD, Chao-Yuan Yeh, MD, Cheng-Kun Yang, Sheng-Chuan Huang, MD, Feng Ming Tien, MD, Chi-Yuan Yao, MD, Chieh-Lung Cheng, MD, Ming-Kai Chuang, MD, Hwei-Fang Tien, MD, PhD, Qun-Yi Zhang, Wei-Han Hsu, Sheng-Cheih Chou

Blood (2019) 134 (Supplement_1): 2084.

DOI: https://doi.org/10.1182/blood-2019-125322

Published: 2019

Journal Articles

Diplotype Analysis of NUDT15 Variants By Targeted Sequencing in Pediatric Acute Lymphoblastic Leukemia

Chih-Hsiang Yu, Ya-Hsuan Chang, PhD, Wen-Chien Chou, MD, PhD, Der-Shiun Wang, MD, Shu-Wha Lin, PhD, Hsuan-Yu Chen, PhD, Yung-Li Yang, MD PhD

Blood (2019) 134 (Supplement_1): 1305.

DOI: https://doi.org/10.1182/blood-2019-124053

Published: 2019

Journal Articles

Minimal Residual Disease Monitoring By Next-Generation Sequencing in Patients with Acute Myeloid Leukemia: MRD Positivity after First Consolidation Chemotherapy Can Better Predict Clinical Outcomes Than That after Induction Chemotherapy

Cheng-Hong Tsai, MD MSc, Jih-Luh Tang, MD, PhD, Feng-Ming Tien, MD, M.Sc, Yuan-Yeh Kuo, PhD, Chien-Chin Lin, MD, Mei-Hsuan Tseng, M.Sc., Yen-Ling Peng, M.Sc., Ming-Chih Liu, Chia-Wen Liu, Ming Yao, Liang-In Lin, PhD, Wen-Chien Chou, MD, PhD, Chien-Yu Chen, PhD, Hsin-An Hou, Hwei-Fang Tien, MD, PhD

Blood (2019) 134 (Supplement_1): 2698.

DOI: https://doi.org/10.1182/blood-2019-126870

Published: 2019

Journal Articles

The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia

Chao-Hung Wei, MD, Cheng-Hong Tsai, MD, M.Sc., Jih-Luh Tang, MD, PhD, Yuan-Yeh Kuo, PhD, Feng-Ming Tien, MD, M.Sc, Chien-Chin Lin, MD, Mei-Hsuan Tseng, M.Sc., Yen-Ling Peng, Ming-Chih Liu, Chia-Wen Liu, Ming Yao, MD, Liang-In Lin, PhD, Wen-Chien Chou, MD, PhD, Chien-Yu Chen, PhD, Hsin-An Hou, Hwei-Fang Tien, MD, PhD

Blood (2019) 134 (Supplement_1): 2705.

DOI: https://doi.org/10.1182/blood-2019-124657

Published: 2019

Journal Articles

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients

Blood (2019) 133 (10): 1140–1151.

DOI: https://doi.org/10.1182/blood-2018-05-852822

Published: 2019

Includes: Supplemental data

2 3 4

NARROW

Effect of Mutation Allele Frequency on the Risk Stratification of Myelodysplastic Syndrome Patients

Conditional Knock-out of Phf6 Decreases CD44 Expression on Naïve CD4 + T Cells and Skews the Differentiation Toward Regulatory T Cells in Mice

A Three Gene Leukemic Stem Cell Signature Score Is Robustly Prognostic in Chronic Myelomonocytic Leukemia

Prognostic Relevance of Adult Acute Myeloid Leukemia Patients According to the 2022 European Leukemianet Risk Stratiﬁcation

Cost-Effectiveness Analysis of Frontline Treatment with Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Metabolic Profiling Reveals Cellular Reprogramming of Acute Myeloid Leukemia By Omipalisib through Serine Synthesis Pathway

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

RUNX1 Expression Can be Complementary to RUNX1 Mutation in MDS Prognostication

Epidemiology of Light-Chain Amyloidosis: A Population-Based Cohort Study in Taiwan

Accurate Prediction of Gene Mutations with Flow Cytometry Immune-Phenotyping By Machine Learning Algorithm

Risk Factors for Thrombotic Events in Patients with PNH: A Nested Case-Control Study in the International PNH Registry

Prognostic Prediction with Static-Dynamic Clinical and Pathological Parameters By Machine Learning Algorithm in Acute Lymphoblastic Leukemia

Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Automatic Bone Marrow Cell Identification and Classification By Deep Neural Network

Diplotype Analysis of NUDT15 Variants By Targeted Sequencing in Pediatric Acute Lymphoblastic Leukemia

Minimal Residual Disease Monitoring By Next-Generation Sequencing in Patients with Acute Myeloid Leukemia: MRD Positivity after First Consolidation Chemotherapy Can Better Predict Clinical Outcomes Than That after Induction Chemotherapy

The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only